Po­sei­da pro­motes cell ther­a­py pres­i­dent to CEO; Af­ter IPO, Neumo­ra ap­points R&D chief

→ The CEO post is chang­ing hands once again at Po­sei­da, as Kristin Yare­ma gets pro­mot­ed to the top spot on Jan. 1 and Mark Ger­gen will take on the role of ex­ec­u­tive chair­man. At the con­clu­sion of her sev­en years with Am­gen (2013-20), Yare­ma was bumped up to VP & ther­a­peu­tic area head for glob­al prod­uct strat­e­gy & com­mer­cial in­no­va­tion in hema­tol­ogy-on­col­o­gy. She then spent more than two years at Atara Bio­ther­a­peu­tics as com­mer­cial chief be­fore be­com­ing pres­i­dent of cell ther­a­py at Po­sei­da in April. Ger­gen, the for­mer CBO at the San Diego CAR-T biotech, suc­ceed­ed Er­ic Os­tertag as chief ex­ec­u­tive on Feb. 1, 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER